Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis

Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects.